VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
about
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathyMolecular mapping and functional characterization of the VEGF164 heparin-binding domainPegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.Pegaptanib sodium for the treatment of neovascular age-related macular degeneration.Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.Role of pegaptanib sodium in the treatment of neovascular age-related macular degenerationRecombinant human VEGF165b inhibits experimental choroidal neovascularizationThe role of RPE cell-associated VEGF₁₈₉ in choroidal endothelial cell transmigration across the RPE.Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis)Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body responseFundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseasesVEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions.VEGF-targeted therapy and beyond: pharmacotherapy and emerging treatments in agerelated macular degeneration.Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cellsRole of the endothelium in inflammatory bowel diseases.Murine rVEGF164b, an inhibitory VEGF reduces VEGF-A-dependent endothelial proliferation and barrier dysfunction.The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro studyInhibitors of cytochrome P450 4A suppress angiogenic responsesVEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP.Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.Vascular endothelial growth factor biology: clinical implications for ocular treatmentsInhibition by tyroserleutide (YSL) on the invasion and adhesion of the mouse melanoma cell.Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.VEGF₁₆₄ isoform specific regulation of T-cell-dependent experimental colitis in mice.Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues.Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis.Strategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.Vascular endothelial growth factor in eye disease.Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420A Role for PPARbeta/delta in Ocular AngiogenesisPhotoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiencyVEGF-A isoform modulation in an preclinical TNBS model of ulcerative colitis: protective effects of a VEGF164b therapy.The effects of oxygen stresses on the development of features of severe retinopathy of prematurity: knowledge from the 50/10 OIR model.Autophagy in Diabetic Retinopathy.An update on the pharmacotherapy of neovascular age-related macular degeneration.Endothelial cAMP deactivates ischemia-reperfusion-induced microvascular hyperpermeability via Rap1-mediated mechanisms.Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy.
P2860
Q27000351-0DA5E87E-B235-41D2-8B9B-F91B586992E1Q27021701-B7E299DC-17EF-408C-B458-088EB9D7DF29Q28505465-52687F9E-AB05-486E-B419-2D1880F4B548Q30440705-0B92F50F-4CA6-4D70-980E-11996D8AFA4AQ33216197-B1CC8AA3-E2AF-451F-B79E-B690C5BBCE60Q33267903-EC7A97BE-ADB4-4269-88DE-18205E586D24Q33492369-0932C198-E624-4E10-86B3-04A845B91BA6Q33541827-A45CA0CF-34E5-4AAB-A995-718223CF789CQ33681817-96DE105A-B1D3-4481-982C-EC22F118DE8BQ33787955-3B610208-8954-4E16-8F10-DA4E7000DEA6Q33804469-6BC01A0F-DB22-44FC-9DA6-9353A7DDAC65Q33840787-843F6523-5554-48CA-AD10-592898385838Q34081464-A804BFE2-18F3-46CC-A1DD-AEDDC89A2F04Q34081923-01394F37-9798-440E-9E82-C249077781D0Q34390960-3DAA3D43-231A-4640-841A-65766F65F19DQ34579746-6365FA61-1DE3-46B7-9BD3-E640DA46CB63Q34675574-67593BFB-ABDB-4AA9-8054-D25E51C9EE0FQ34704521-CD0FC6AA-3C89-49A8-967C-D0CEB86FB20AQ35083648-B8946298-72B1-4EF6-B6FC-89C5459ED3AFQ35688115-C3263E8C-BFB8-429D-B1B7-C64D54448A5FQ35688128-C07E89A5-DBA8-4BED-B528-6D47D5015480Q35762769-06BA5ABD-D11E-4DCC-8AF9-B8880E1807E2Q35795721-7D2202AD-B717-405B-8FCC-B1C8980A4123Q36248876-C6710F2F-88C9-493A-8DF8-D2C882488823Q36468115-8173B9E6-B206-4EAE-976D-A86CC0CE05B4Q36673663-FF911C6A-DD34-4DC0-B926-3BBC448E8BABQ36702612-75252ED5-57EB-4EA5-8C83-9837F7D83199Q36803301-805FDC42-8963-46AB-A5F7-59487EBC33D5Q36877837-E2680AE9-136F-4D60-A867-6FA1283C8575Q36904857-CA5BACA6-CD37-4E1B-B7D3-1604C1878D2AQ36929380-FADEBF41-0FBB-4FEE-A1A7-0C10E060B811Q36960552-70466E0E-D74E-49E1-B5D1-E7583E0F15DDQ37125975-1AEADBC3-44AC-4EBA-A6B1-5FE0D7A96C26Q37308169-43DCF5BD-D3AC-410A-B179-47D7932D80B0Q37359869-690D74B6-186D-434A-9F49-6CF20B61D435Q37565247-4B9580EB-21F0-465A-B48C-6B9F7CEE75A2Q37677015-E7E7922A-5512-4260-8124-5400E39227C8Q38096462-8F5BAEC8-38B0-4351-A1D5-6441DEC046F1Q38801310-6DF07FEE-BADC-4D21-8E48-8A64EA62DF3DQ38895113-157D6E88-FB1F-4969-9B97-06F5B189949C
P2860
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
VEGF164(165) as the pathologic ...... ses through VEGFR1 and VEGFR2.
@en
type
label
VEGF164(165) as the pathologic ...... ses through VEGFR1 and VEGFR2.
@en
prefLabel
VEGF164(165) as the pathologic ...... ses through VEGFR1 and VEGFR2.
@en
P2093
P356
P1476
VEGF164(165) as the pathologic ...... ses through VEGFR1 and VEGFR2.
@en
P2093
Anthony P Adamis
Darlene Dartt
David T Shima
Johnny Moore
Kenji Yamashiro
Matthew Golding
Shiro Amano
Susumu Ishida
Tara Moore
Tomohiko Usui
P304
P356
10.1167/IOVS.03-0106
P407
P577
2004-02-01T00:00:00Z